A recent study involving seven patients with R/R AML suggested that sequential treatment with CD7-CAR-T cells followed by haploidentical HSCT may be both safe and effective, leading to durable responses.324 Other strategies include autologous nanobody-derived fratricide-resistant CD7-CAR-T cells. This evidence concerns the gene CD7 and acute myeloid leukemia.